In silico methods to identify meat-derived prolyl endopeptidase inhibitors.

According to the World Health Organization (WHO), approximately 450 million people suffer from mental or neurological disorders and five of the ten leading causes of disability and premature death worldwide are psychiatric conditions. Social, biological and neurological sciences provided extensive understanding into the role of risk and protective factors in the development of mental disorders and poor mental health. Altered activity of a number of enzymes, such as prolyl endopeptidase (PEP, EC 3.4.21.26), has been linked to the prevention and treatment of a number of mental disorders, including anxiety, depression and Alzheimer's disease. The inhibition of PEP has potential for use in the prevention and in the treatment of mental disorders. The objective of this work was to identify PEP-inhibitory peptides from meat proteins using in silico methods. In this paper, five proteins commonly found in meat by-products were evaluated as a substrate for use in the generation of PEP inhibitory peptides. These include serum albumin, collagen and myosin. These proteins were cleaved in silico using BIOPEP and ExPASy PeptideCutter and the generated peptides were compared to known PEP-inhibiting peptides in the database of BIOPEP. A number of novel PEP inhibitory peptide sequences were identified in this study, including PPL, APPH, IPP and PPG with corresponding IC50 values of 2.86, 3.95, 4.02 and 2.70 mM, respectively. This work demonstrates the usefulness of in silico analysis for predicting the release of PEP-inhibiting peptides from meat proteins.

[1]  H. Cheung,et al.  Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. , 1980, The Journal of biological chemistry.

[2]  C. Schwerk,et al.  Culture models to study leukocyte trafficking across the choroid plexus , 2013, Fluids and Barriers of the CNS.

[3]  I. Ashmarin,et al.  The simplest proline-containing peptides PG, GP, PGP, and GPGG: regulatory activity and possible sources of biosynthesis. , 1998, Biochemistry. Biokhimiia.

[4]  R. Watson,et al.  Passion fruit extract in osteoarthritis symptom treatment , 2011 .

[5]  V. Fülöp,et al.  Structures of Prolyl Oligopeptidase Substrate/Inhibitor Complexes , 2001, The Journal of Biological Chemistry.

[6]  L. Grélot,et al.  Potential of Substance P Antagonists as Antiemetics , 2000, Drugs.

[7]  The UniProt Consortium,et al.  Reorganizing the protein space at the Universal Protein Resource (UniProt) , 2011, Nucleic Acids Res..

[8]  J. Kozarich,et al.  Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. , 2003, Current opinion in chemical biology.

[9]  A. Iwaniak,et al.  BIOPEP database and other programs for processing bioactive peptide sequences. , 2008, Journal of AOAC International.

[10]  L. Polgár,et al.  How can the mood stabilizer VPA limit both mania and depression? , 2005, Molecular and Cellular Neuroscience.

[11]  N. Nio,et al.  Inhibition of prolyl endopeptidase by synthetic beta-casein peptides and their derivatives with a C-terminal prolinol or prolinal. , 1992, Bioscience, biotechnology, and biochemistry.

[12]  Richard L. Bowen,et al.  The gonadotropin connection in Alzheimer’s disease , 2005, Endocrine.

[13]  J. Gutiérrez-Uribe,et al.  Bioactive peptides and hydrolysates from pulses and their potential use as functional ingredients. , 2014, Journal of food science.

[14]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[15]  E. D. de Mejia,et al.  A New Frontier in Soy Bioactive Peptides that May Prevent Age-related Chronic Diseases. , 2005, Comprehensive reviews in food science and food safety.

[16]  H. Hinz,et al.  Partial molar volumes of proteins: amino acid side-chain contributions derived from the partial molar volumes of some tripeptides over the temperature range 10-90 degrees C. , 1999, Biophysical chemistry.

[17]  M. Hayes,et al.  Identification of novel dipeptidyl peptidase-IV and angiotensin-I-converting enzyme inhibitory peptides from meat proteins using in silico analysis , 2014, Peptides.

[18]  L. Frewer,et al.  2 – Sensory influences on food choice and food intake , 2006 .

[19]  S. Saxena,et al.  Prevention of mental disorders : effective interventions and policy options : summary report , 2004 .

[20]  S. Maruyama,et al.  Prolyl Endopeptidase Inhibitory Activity of Peptides in the Repeated Sequence of Various Proline-Rich Proteins , 1992 .

[21]  M. Hayes,et al.  Bioactive peptides from meat muscle and by-products: generation, functionality and application as functional ingredients. , 2014, Meat science.

[22]  A. Janecka,et al.  Substance P: transmitter of nociception (Minireview). , 2000, Endocrine regulations.

[23]  L. Juillerat-Jeanneret,et al.  Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. , 2010, Journal of medicinal chemistry.

[24]  V. Fülöp,et al.  Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. , 1998, Cell.

[25]  Niall J. Haslam,et al.  Towards the Improved Discovery and Design of Functional Peptides: Common Features of Diverse Classes Permit Generalized Prediction of Bioactivity , 2012, PloS one.

[26]  Emanuele Tomba,et al.  Prediction of protein solubility in Escherichia coli using logistic regression , 2010, Biotechnology and bioengineering.

[27]  T. Ohmori,et al.  Isolation of prolylendopeptidase-inhibiting peptides from bovine brain. , 1994, Biochemical and biophysical research communications.

[28]  M. Hayes,et al.  Angiotensin-I-converting enzyme and prolyl endopeptidase inhibitory peptides from natural sources with a focus on marine processing by-products. , 2011, Food chemistry.

[29]  Efsa Panel on Dietetic Products.  Scientific Opinion on the substantiation of a health claim related to isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) and maintenance of normal blood pressure pursuant to Article 13(5) of Regulation (EC) No 1924/2006 , 2011 .

[30]  P. Couraud,et al.  The hCMEC/D3 cell line as a model of the human blood brain barrier , 2013, Fluids and Barriers of the CNS.

[31]  Rahul Kumar,et al.  In Silico Approach for Predicting Toxicity of Peptides and Proteins , 2013, PloS one.

[32]  D. Shields,et al.  In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors , 2014, Peptides.

[33]  A. Pripp.  Quantitative structure-activity relationship of prolyl oligopeptidase inhibitory peptides derived from beta-casein using simple amino acid descriptors. , 2006, Journal of agricultural and food chemistry.

[34]  T. Sørhaug,et al.  Screening for peptides from fish and cheese inhibitory to prolyl endopeptidase. , 2004, Die Nahrung.

[35]  J. A. García-Horsman,et al.  On the role of prolyl oligopeptidase in health and disease , 2007, Neuropeptides.

[36]  P. Lestage,et al.  S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. , 2006, CNS drug reviews.

[37]  J. Silberg,et al.  A transposase strategy for creating libraries of circularly permuted proteins , 2012, Nucleic acids research.

[38]  M. Danhof,et al.  Drug transport across the blood-brain barrier , 1992, Pharmaceutisch Weekblad.